respiratory-depression | Media Room

Press Release Sep 24, 2024

Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States

Press Release Sep 10, 2024

Enalare Therapeutics Receives Additional Funding From BARDA to Further Advance the Development of Agnostic Respiratory Stimulant (ENA-001)

Press Release Feb 15, 2024

Enalare Therapeutics Announces Publication of a Clinical Study Demonstrating the Effect of ENA-001 on Improving Propofol-Induced Depression of the Hypoxic Ventilatory Response

Press Release Jan 19, 2021

Enalare Therapeutics Appoints Mark Coleman M.D. to Its Board of Directors

The Addition of Dr. Coleman Further Enhances the Company's Deep Medical, Enterprise Leadership, and Capital Markets Experience

Press Release Nov 17, 2020

Enalare Therapeutics Appoints 3 New Members to Its Board of Directors

The addition of Gino Santini, Bob Yedid, and Joe Petko Significantly Expands Company's Pharmaceutical and Financial Markets Experience and Capabilities

Press Release Nov 9, 2020

Enalare Therapeutics Appoints Daniel Motto as Chief Business Officer

Press Release Oct 30, 2020

Enalare Therapeutics Appoints Herm Cukier as Executive Chairman, President, and CEO

Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory conditions, announced today that it has appointed biopharma industry veteran Herm Cukier as its Executive Chairman of the Board, President, and Chief Executive Officer.